Pfizer, PFE
Digest more
Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...
The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...
Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...
Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...
Better still, if interest rates drop, as they're generally expected to over the coming year, the interest income you'll get ...
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...
TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...
Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback